Laurent Nyssen1, Pierre Delanaye2, Caroline Le Goff1, Stéphanie Peeters1, Étienne Cavalier3. 1. Department of Clinical Chemistry, University of Liège, CHU Sart-Tilman, 4000 Liège, Belgium. 2. Department of Nephrology and Hypertension, University of Liège, CHU Sart-Tilman, 4000 Liège, Belgium. 3. Department of Clinical Chemistry, University of Liège, CHU Sart-Tilman, 4000 Liège, Belgium. Electronic address: etienne.cavalier@chu.ulg.ac.be.
Abstract
BACKGROUND: Chronic kidney disease (CKD) is diagnosed and explored through the determination of the glomerular filtration rate (GFR). Our goal was to develop a simple LC-MS method for the determination in serum of 2 popular GFR markers, contrast agents iohexol and iothalamate, for routine use and comparison studies between the two markers. A similar contrast agent, ioversol, was used as an internal standard and the method underwent a rigorous validation protocol based on β-expectation tolerance intervals. METHODS: We adapted the HPLC-UV method from Cavalier et al. to our LC-MS system. Data treatment for the validation was performed using Multiquant 3.0 (Sciex, Framingham, MA, USA) and e.noval 3.0 software (Arlenda, Liège, Belgium). RESULTS: According to the validation results our method will give accurate and reliable results for concentrations ranging from 6.8 to 250μg/ml for iohexol and 6.15μg/ml to 250μg/ml for iothalamate. In our practice these intervals are sufficient to determine both compounds in most patient samples. Samples with higher detected concentrations can always be diluted into range. CONCLUSION: With its internal standard and extensive validation, our method is now ready for routine and clinical research use. Copyright Â
BACKGROUND:Chronic kidney disease (CKD) is diagnosed and explored through the determination of the glomerular filtration rate (GFR). Our goal was to develop a simple LC-MS method for the determination in serum of 2 popular GFR markers, contrast agents iohexol and iothalamate, for routine use and comparison studies between the two markers. A similar contrast agent, ioversol, was used as an internal standard and the method underwent a rigorous validation protocol based on β-expectation tolerance intervals. METHODS: We adapted the HPLC-UV method from Cavalier et al. to our LC-MS system. Data treatment for the validation was performed using Multiquant 3.0 (Sciex, Framingham, MA, USA) and e.noval 3.0 software (Arlenda, Liège, Belgium). RESULTS: According to the validation results our method will give accurate and reliable results for concentrations ranging from 6.8 to 250μg/ml for iohexol and 6.15μg/ml to 250μg/ml for iothalamate. In our practice these intervals are sufficient to determine both compounds in most patient samples. Samples with higher detected concentrations can always be diluted into range. CONCLUSION: With its internal standard and extensive validation, our method is now ready for routine and clinical research use. Copyright Â
Authors: Julianne L Holleran; Robert A Parise; Jianxia Guo; Brian F Kiesel; Sarah E Taylor; S Percy Ivy; Edward Chu; Jan H Beumer Journal: J Pharm Biomed Anal Date: 2020-07-07 Impact factor: 3.935
Authors: Justine B Bukabau; Ernest K Sumaili; Etienne Cavalier; Hans Pottel; Bejos Kifakiou; Aliocha Nkodila; Jean Robert R Makulo; Vieux M Mokoli; Chantal V Zinga; Augustin L Longo; Yannick M Engole; Yannick M Nlandu; François B Lepira; Nazaire M Nseka; Jean Marie Krzesinski; Pierre Delanaye Journal: PLoS One Date: 2018-03-02 Impact factor: 3.240